CHAPTER N0.

18

# The Role of Prebiotics and Synbiotics in Gut Health Modulation

MINAHIL MANSOOR[1], SANA JAVED[1*], BISMA FATIMA[1], JAWERIA BATOOL[1], MINAHIL ABID[1], ANAM AZAM[1]

[1]Department of Pharmacy, The University of Faisalabad, Faisalabad, Pakistan
[*]Corresponding author: sanajaved.pharm@tuf.edu.pk

**Summary:** The gut is an important part of the human body since it is a complex system of interaction between the gastrointestinal tract, the gut microbiota, the immune system, and the metabolic processes. The latest developments in microbiome biology have reiterated the roles of regulating gut health as a therapeutic intervention in the prevention and treatment of numerous metabolic, inflammatory, and gastrointestinal conditions. Emerging evidence on the use of prebiotics, non-digestible food components, as selective stimulators of beneficial microorganisms and synbiotics, which are prebiotics combined with probiotics with synergistic effects, has led to significant interest in their role in the promotion of intestinal homeostasis. This chapter examines the mechanistic understanding of the role of prebiotics and synbiotics in the maintenance of gut microbiota, improving of barrier functionality, and regulation of immune and metabolic operations. In addition, there is an emerging clinical evidence of the synbiotics to enhance gastrointestinal wellbeing, decrease colonization by pathogens, and to enhance host metabolism. All in all, the knowledge of the modulatory capacity of prebiotics and synbiotics can form the scientific basis of the creation of the functional foods and nutraceuticals that can be used to maintain the health of the gut and overall well-being.

**Keywords:** Prebiotic, Gut health, Synbiotic, Microorganism

## INTRODUCTION

By thoroughly examining the theories, varieties, modes of action, and sources of these substances, this chapter aims to investigate and ascertain the role that synbiotics and prebiotics play in preserving gut health. This chapter also deals with the health benefits that these compounds confer to gut microbiota and immune, metabolic and mental health. Moreover, it aims at the clinical evidence and applications of these compounds in treating various diseases. This chapter also highlights the challenges and limitations of prebiotics and synbiotics and how future trends and directions are being employed for their development and application in nutrition and medicine.

The concept of gut health in medical research and the food industry presupposes a number of positive features of the gastrointestinal tract (GIT) such as the proper production of digestive juices and nutrient absorption, the absence of gastrointestinal diseases, the stable and balanced intestinal microbiota, the effective immune system, and the feeling of wellbeing. The digestive system is very crucial in maintaining good health and wellbeing (Bischoff, 2011). Animal research and other small amount of human data show that the stomach interacts with positive bacteria which help in the digestion process due to their enzymatic activity (Blaut & Clavel, 2007; Vrieze et al., 2010). These microbes control vital epithelial and immune processes that are vital in the preservation of gut and general health (Chung & Kasper, 2010; Sharma et al., 2010). Also, the gut and the brain can communicate through the vagus nerve and other hormones and affect energy uptake, mood, and wellbeing (Tsurugizawa et al., 2009).

## THE HUMAN GUT MICROBIOTA

### Composition and Role

The digestive system of humans contains a multitude of microorganisms, with the majority belonging to the domain Bacteria. It has been stated that the human colon contains 10 billion to 1 trillion living bacteria per gram (Collins & Reid, 2016). The microbial communities present in the stomach, small intestine, and large intestine are necessary for maintaining human health. Most of these microbes, primarily anaerobes, inhabit the large intestine. The establishment of the microbiota starts shortly after birth, characterized by a dominance of facultative anaerobes like Enterobacter and Streptococcus. This starting population is subsequently supplanted by anaerobes, such as *Escherichia*, *Bacteroides*, *Bifidobacterium*, *Ruminococcus, Prevotella*, and *Clostridium* (Tanaka & Nakayama, 2017). At the age of one, a child's microbiota features increased levels of *Akkermansia muciniphila*, Bacteroides, *Clostridium* spp. Clostridium coccoides species, and Veillonella (Rinninella et al., 2019). Within the first three years of birth, a child's microbiota develops virtually completely (Yatsunenko et al., 2012).

Research shows that three bacterial phyla, Firmicutes, Actinobacteria and Bacteroidetes are prevalent in adulthood (Yatsunenko et al., 2012). Due to various impacts on host health and physiology, there is increasing interest in comprehending the function and role of gut microbial communities. The composition of microbiota varies throughout the GIT due to alterations in physicochemical conditions and the availability of substrates. The GI microbiome blocks the establishment of potentially harmful

How to Cite: Mansoor M, S Javed, B Fatima, J Batool, M Abid, A Azam, 2025. The Role of Prebiotics and Synbiotics in Gut Health Modulation. In: Advances in Animal and Life Sciences (Sindhu ZuD, M Imran, MA Zafar & S Yousaf, Eds.): FahumSci, Lahore, Pakistan, pp. 121-127. ISBN: 978-627-7745-12-7. https://doi.org/10.61748/AALS.2025/18

microorganisms, supplies energy from undigested substances (such as carbohydrates and other nutrients) to the gut wall, and modulates the mucosal immune system, both educating the inexperienced infant immune system and acting as a vital source of immune enhancers throughout life (Bouskra et al., 2008; Hsiao et al., 2008; Kinross et al., 2008; Mai & Draganov, 2009; Round & Mazmanian, 2009; Possemiers et al., 2009). Consequently, the GI microbiota plays an effective role in maintaining energy balance, inhibits mucosal infections, and probably reduces hypersensitivity of the immune system. Crucially, it aids in preserving a functional GI barrier, which appears to be strongly associated with infectious, inflammatory, and allergic conditions (Groschwitz & Hogan, 2009; Preidis & Versalovic, 2009).

### Factors Influencing Gut Microbiota

The disturbance of the gastrointestinal microbiome by oral administration of antibiotics (Dethlefsen et al., 2008; Jeong et al., 2009; Tanaka et al., 2009) or an imbalanced diet with a high carbohydrate content (Spruss & Bergheim, 2009; Sonnenburg et al., 2010), can impair the local defense system of the host. Equally, any damage to the epithelial layer, the immune cells or the enteric nervous system (ENS) can change the composition and the activity of the gut microbiota. The condition of the gastrointestinal barrier is thus crucial in determining gut health and may be impaired by local pathophysiological events, including increased epithelial permeability caused by infection or dysfunction of immune cells, as well as by systemic influences, including poor oxygenation of intensive care patients, malnutrition in the elderly or cancer patients, and the neural alteration of neural input induced by chronic disease or depression (De-Souza & Greene, 2005; Iapichino et al., 2008; Collins & Bercik, 2009; Kinross et al., 2009; Rhee et al., 2009). Therefore, a wide and healthy gut microbiota, as well as a healthy gastrointestinal barrier that protects against pathogenic bacteria and co-operates with the positive ones, is crucial in terms of a healthy gut (Bischoff, 2011).

## PRE-BIOTICS

Marcel Roberfroid and Glenn Gibson were the first scientists to propose the idea of prebiotics (Gibson & Roberfroid, 1995). They considered a prebiotic to be a non-digestible food matter that positively influences the host by selectively inducing the development and/or activity of defined bacteria in the colon, consequently enhancing the health of a host. The definition to a large extent was similar during the period of fifteen years. With this initial appreciation, only several carbohydrate-based compounds (including inulin, fructooligosaccharides (FOS) including short and long-chain β-fructans, galactooligosaccharides (GOS), and lactulose) were considered true prebiotics. Subsequently, in the 2008 Annual Meeting of the International Scientific Association of Probiotics and Prebiotics (ISAPP), scholars re-defined dietary prebiotics as selectively fermented ingredients producing certain changes in intestinal microbiota composition and/or function and bringing about health benefits to the host (Gibson et al., 2010).

### Mode of Action

The prebiotics that are not digested and reach the large intestine are then digested by bacteria that are present in the gut. They absorb water as they pass through the intestinal lumen and thus augment the amount of intestinal contents. This increased and reduced compact structure provides the best environment in which bacteria can thrive. In microbial fermentation of prebiotics, short-chain fatty acids (SCFAs) are generated and they play an important role in the health of the intestines. They stimulate the growth of good microbes, prevent bad microorganisms, increase growth, repair, and regeneration of epithelial cells, increase mucus-secretions, and control intestinal PH- this in effect suppresses the proliferation of bad bacteria. Furthermore, prebiotics enhance the absorption of minerals, including calcium, iron, magnesium, help to reduce the level of blood cholesterol, and have a beneficial impact on the liver metabolism of proteins and glucose (Cummings & Macfarlane, 2002; Van Loo, 2004; Gibson et al., 2017).

### Types of Prebiotics

Prebiotics are varied and mostly fall under the carbohydrate (CHO) category especially the oligosaccharide carbohydrates (OSCs). These OSCs have been considered by most of the scientific literature as the primary forms of prebiotics; although recent studies indicate that non-carbohydrate compounds could also have prebiotic activity (Davani-Davari et al., 2019).

**Furan:** Fructose molecules are also found as fructans, such as oligofructose, fructooligosaccharides (FOS), which are linear chains of fructose molecules attached by β (2-1) glycosidic bonds, and normally to a glucose molecule attached by the same linkage type. Types also vary in their degree of polymerization (DP) inulin can have DP of up to 60, whereas FOS usually has a DP less than 10. Previous studies have shown that lactic acid bacteria are the primary stimulator by fructans but, more recent studies have also revealed that the chain length of fructans is a decisive factor in which bacterial species can ferment it (Scott et al., 2014). Fructans, in turn, may induce the development of different useful bacteria species in the gut either directly or indirectly (Davani-Davari et al., 2019).

**GOS:** Galacto-oligosaccharides (GOS), which are products of lactose, can be categorized into two major forms, (i) GOS molecules with more galactose units at C3, C4 or C6 sites, and (ii) GOS molecules formed by enzymatic trans-glycosylation of lactose. An enzyme reaction yields mainly a blend of tri -pentasaccharides with Beta (1-6), Beta (1-3), and Beta (1-4) linkages. The group can also be called trans-galacto-oligosaccharides (TOS) (Macfarlane et al., 2008; Gibson et al., 2010). GOS has a strong effect on the growth of Bifidobacteria and Lactobacilli particularly in infants where Bifidobacteria have an intense response to GOS supplementation. Also, GOS favors the growth of Bacteroidetes, Enterobacteria, and Firmicutes, but less than Bifidobacteria. There are GOS obtained out of lactulose, which is an isomer of lactose, and these forms are also known as prebiotics (Gibson et al., 2010). Besides, other varieties of GOS, formed by the further elongation of sucrose, are Raffinose Family Oligosaccharides (RFOs). Nevertheless, they have an unknown impact on the composition of gut microbiota (Johnson et al., 2013, Whelan, 2013).

**Glucose-derived oligosaccharides and starch:** Resistant starch (RS) is one of the glucose-based prebiotics that are noteworthy due to being a starch fraction that is not digested in the upper gastrointestinal tract. RS is a prebiotic because it induces the production of large levels of the anti-inflammatory and regenerative short-chain fatty acid butyrate (Sánchez-Zapata et al., 2011). The Firmicutes phylum has the most ability to digest resistant starch (Walker et al., 2011). *In-vitro* studies have shown that *Bifidobacterium adolescentis* and *Ruminococcus bromii* are capable of degrading RS with *Bacteroides thetaiotaomicron* and *Eubacterium rectale* playing a smaller role. Nonetheless, the RS degradation in mixed fecal cultures cannot take place efficiently without *Ruminococcus bromii* (Ze et al., 2012). Polydextrose is another glucose-based oligosaccharide which is branched glucan network with multiple glycosidic bonds. Early signs indicate that it can help in stimulating Bifidobacteria but this is yet to be proved conclusively (Costabile et al., 2012).

**Other oligosaccharides:** Prebiotic oligosaccharides are derived by the polysaccharide pectin, and are also called pectic oligosaccharides (POS). These polymers are based on rhamnose or galacturonic acid chains: homogalacturonan. The structural differences are brought by methyl esterification of carboxyl groups and at C2 or C3 positions acetylation. Moreover, POS can have side chains connected by ferulic acid or sugars (xylose, galactose, and arabinose) (Yoo et al., 2012). The composition and biological activity of POSs vary greatly, as they are made of materials of different sources, and this fact predetermines their structural diversity (Gullón et al., 2013).

**Non-Carbohydrate oligosaccharides:** While carbohydrates more readily fulfill the prebiotic definition, certain non-carbohydrate compounds, like cocoa-derived flavanols, are also suggested for classification as prebiotics. Experiments both in situ and in vivo demonstrate that flavanols can encourage lactic acid bacteria (Tzounis et al., 2011).

## Sources of Prebiotics

Prebiotics can be sourced from different origins, such as breast milk, soybeans, and uncooked oats (Pokusaeva et al., 2011; Pandey et al., 2015). The most popular prebiotics are oligosaccharides, which are present in plants like artichokes, chicory, onions, and asparagus (Pandey et al., 2015). Oligosaccharides can enhance the gastrointestinal system through fermentation and the growth of beneficial bacterial types. For instance, FOS enhances the development of bifidobacteria in vivo. Inulin and oligofructose also enhance the levels of bifidobacteria in the colon (Hidaka et al., 1986; Hidaka et al., 1991). Currently, probiotics are frequently included as additives in dairy items, meat products, and drinks like health beverages. It has been recently indicated that seaweed could be used as a beneficial source of polysaccharide elements, which may function as prebiotics (Cherry et al., 2019).

## Health Benefits of Prebiotics

Prebiotic consumption is associated with much less health outcomes than dietary fiber. Nevertheless, it has been proposed that consuming prebiotics could lower the duration and frequency of antibiotic-related and infectious diarrhea; alleviate the symptoms and inflammation linked to IBS; encourage feelings of fullness and weight reduction while helping prevent obesity; protective benefits against colon cancer; decrease certain risk factors of cardiovascular diseases; and improve the systemic availability and absorption of minerals like calcium, magnesium, and potentially iron (Cherry et al., 2019).

**Gastroenteritis:** this is a prevalent illness that typically arises from tainted water or consuming food with harmful microbes or toxicants. The agent that causes gastroenteritis include, *Clostridium perfringens*, *Campylobacter jejuni*, *Yersinia enterocolitica*, *Vibrio cholera*, *Salmonella*, *Shigella*, and *Escherichia coli*. These infectious agents proliferate and establish themselves in the GI tract, invading host tissue or secreting toxins in food prior to consumption. These poisons interfere with the operations of the intestinal mucosa, leading to diarrhea, nausea and emesis (Hui et al., 1994). Consequently, prebiotics helps to prevent gastroenteritis by promoting the growth of beneficial microorganisms in the large intestine.

**Inflammatory bowel disease (IBD):** In industrialized countries, about one in every 1000 persons suffers with CD (Crohn's disease) and UC (ulcerative colitis). They significantly decrease the quality of life for patients but are not fatal (Card et al., 2003). The reasons behind these diseases are still unclear; nonetheless, notable advancements in understanding the etiology have been achieved over the last two to three decades. For instance, it has become evident that the interplay of genetic inclination (Ahmad et al., 2004), loss of tolerance to common antigenic stimuli and dysregulation of inflammatory responses (Duchmann et al., 1996) and environmental factors all play a crucial role in disease development (Szilagyi, 2005). By affecting the trophic activities of the microbiota, prebiotics have a positive effect on preventing IBD. By promoting the intestinal production of short chain fatty acids (SCFAs), inulin encourages the growth of native bifidobacteria or lactobacilli. These effects are linked to decreased mucosal inflammation and lower mucosal lesion scores. Because of its prebiotic properties, inulin helps to sustain microbial populations and improve the function of the epithelial barrier (Akram et al., 2019).

**Obesity:** represents a global issue that exists in nearly every nation, impacting all economic and social groups, all age, demographics, all ethnicities, and both sexes. A diet high in calories contributes to obesity and can lead to alterations in the functioning of the gut flora. Alongside lifestyle, genetic and nutritional influences, it has been proposed that obesity might also arise from disruptions in the gut flora, impacting metabolic performance and energy balance (Guirro et al., 2019). Research has indicated that eating foods high in prebiotics is closely linked to positive impacts on obesity, through various mode of action. There is increasing evidence that prebiotic therapy alters gut microbiota composition, promoting the proliferation of Bifidobacterium and Lactobacillus in the gastrointestinal tracts of obese animals (Connolly et al., 2012) while simultaneously decreasing pathogenic microorganism populations like Bacteroidetes and Firmicutes (Parnell & Reimer, 2010).

## SYNBIOTICS

Synbiotics are useful items made when probiotics and prebiotics are combined in formulations. The International Scientific Association for Probiotics and Prebiotics (ISAPP) panel recently updated the definition of synbiotics, which was first established 25 years ago, to read, ‘a blend of live microorganisms and substrate(s) selectively used by host microorganisms that provides a health advantage to the host’ (Swanson et al., 2020).

The co-administered probiotics can selectively use the prebiotic to achieve one or more health benefits if this preparation is designed to complement the host bacteria or to function in concert with them (Pandey et al., 2015). Through targeted promotion of the growth and/or activation of the metabolism of particular beneficial bacteria, a synbiotic product benefits the host by improving the ability to survive and development of live microbial dietary supplements in the gastrointestinal system. Synbiotics refers to synergism, which should be applied to products where the probiotic organism or organisms are preferentially supported by the prebiotic chemical or compounds (Cencic & Chingwaru, 2010).

### Types of Synbiotics

Synbiotics are of two broad categories namely synergistic and complementary. In synergistic synbiotics, prebiotic substrate is specially tailored to be selectively used by the co-administered probiotic microorganisms, hence increasing their positive effects in the host. Conversely, complementary synbiotics are compositions of ingredients that work independently to benefit the host health, but remains in a synergistic effect on using it in combination(Swanson et al., 2020). This is to be understood as the concept stresses that although the prebiotic specifically serves to promote the growth of the microorganism being co-administered it can also indirectly assist in the growth of the rest of the native beneficial microbes in the intestines. The synergy between synbiotics by their nature suggests that such preparations have more health benefits than the individual use of probiotics or prebiotics (Kleerebezem & Führen, 2024). The most widespread synbiotic combinations of Lactobacillus or Bifidobacterium species and fructooligosaccharides (FOS) have proved to be beneficial in enhancing gut health and reducing some symptoms, like constipation (Markowiak & Śliżewska, 2017).

### Clinical applications

**Colorectal cancer:** Combining prebiotics and probiotics has a larger synergistic effect than administering each probiotic separately. Rowland et al. (1998) found that the combination of inulin and B. longum was more effective at reducing azoxymethane-induced ACF than either treatment alone. Another study found that consuming *B. lactis* plus resistant starch increased the apoptotic response to azoxymethane in rats, which was thought to be owing to the resistant starch acting as a metabolic substrate to give optimal probiotic activity (Leu et al., 2005). These findings show that synbiotics may play a role in Colorectal cancer treatment.

**Inflammatory bowel disease (IBD):** The combination of prebiotics and probiotics is regarded as a promising new strategy and offers a chance to investigate their effectiveness and potential in human Inflammatory Bowel Disease. When prebiotics and probiotics are merged in a product to create synergistic effects, they are typically called synbiotics. Numerous instances have shown that prebiotics seem to be more effective when combined with a probiotic as a component of the synbiotic mixture. The term synbiotic describes a synergistic relationship in which the live probiotic organism selectively benefits from the prebiotic component. The synbiotic blend aims to boost the in vivo viability and efficacy of established probiotics to promote or augment the advantageous traits of both products. Recently, the term 'synbiotics' has been redefined to refer to formulations that promote synergism, where probiotics metabolize the accompanying prebiotics to trigger specific rebalancing of the dysbiotic gut and overall host health. Synergistic prebiotics and probiotics promote targeted growth of microbes or enhance particular metabolic functions through gut flora. The availability of the easily fermentable substrate is expected to improve the probiotic's survival. The prebiotic element must also shield the probiotic from proteolysis and gastric acidity, likely by means of steric hindrance and coating of the probiotic. It is essential to choose particular substrate and microbial pairings in synbiotic products that can improve beneficial impacts more than products with prebiotics or probiotics by themselves (Li et al., 2021).

**Constipation:** The phrase constipation refers to symptoms related with evacuation issues. These symptoms are diverse and include lumpy or hard feces, inconsistent bowel motions, severe discomfort, the feeling of obstruction and incomplete evacuation, and the use of manual interventions to promote evacuation (Aziz et al., 2020). Although it is difficult to define, the usual incidence of persistent constipation is thought to be between twelve and nineteen percent. Furthermore, constipation is more frequent in individuals with a poor dietary fiber consumption, women and in the elderly. In humans, synbiotics could lower CTT, enhance stool consistency and boost defecation frequency, but their impact on constipation-related symptoms (stomach pain, bloating, and discomfort) appears controversial, showing no notable impact on the PACSYM score. Consequently, additional RCTs evaluating the impact of synbiotics on constipation necessary because of their debated influence on symptoms related to constipation, aiming to gain a clearer understanding of their role in this condition and for the development of future treatment guidelines for constipation (Araújo & Botelho, 2022).

### Regulatory Aspects

Consumers should recognize the regulations regarding synbiotics and select products from licensed producers that adhere to national criteria. Synbiotic products must be clearly labeled. The labeling and safety of products are two primary areas that regulatory agencies concentrate on. Synbiotics must be labelled to satisfy specific criteria, including a complete description of all components, the amount of each constituent, and their respective ratios. Moreover, all health assertions on the package need to be backed by research data that aligns with national legal criteria (Pandey et al., 2015).

## PERSONALIZED NUTRITION AND FUTURE PERSPECTIVE

Health and wellness are changing their approach to a form of personalized nutrition, specifically applying it to gut health. In contrast to more traditional dietary prescriptions which provide general guidelines, personalized nutrition customizes dietary advice based on the population or microbial/biological phenotype of an individual. This method focuses on genetic aspects, living habits, and, above all, the structure of the intestinal microflora, which becomes a central part of the digestive system, immunity and even mood (Zeevi et al., 2015).

Human gut microbiome is a complex and dynamic environment, which is a community of trillions of microorganisms that include bacteria, viruses, fungi, and archaea. These microbes do not just sit back and enjoy the ride; they are also involved in the metabolism of nutrients and synthesis of vitamins and maintenance of immunity. The gut microbiota composition amongst different individuals is vastly different because of genetics, birth mode, diet, geography and antibiotic exposure (Valdes et al., 2018). The profiles of microbiomes between genetically similar people, including twins, can vary significantly. Such variability affects the metabolism of nutrients among the people, the response to dietary fibers and the production of bioactive compounds such as short-chain fatty acids (SCFAs). Personalised nutrition aims at harnessing this diversity to improve health outcomes by using specific diet plans. Prebiotics are indigestible food substances that selectively enhance the expansion and action of advantageous intestinal microorganisms. Examples of these are inulin, fructooligosaccharides (FOS) and galactooligosaccharides (GOS). These compounds act as food to certain types of microorganisms and thus encourage their growth and increase their metabolic rate. The effects of prebiotics are however not consistent in all people. As an example, inulin can raise the level of Bifidobacteria in an individual but not make a significant effect in another (Gibson et al., 2017). On the same note, GOS may improve the inflammation of a few people and worsen the symptoms of others having irritable bowel syndrome (IBS). The goal of personalized nutrition is to profile the microbial composition of an individual and match certain prebiotics with it to achieve maximum effectiveness and minimum adverse effects.

Synbiotics are a synergistic method of gut modulation (combination of probiotics (live beneficial microbes) and prebiotics). They may be complementary, such as when the components act separately, or synergistic, such as when the prebiotic acts in a specific manner to complement the strain of the probiotic. Individualized synbiotic preparations are becoming popular particularly in clinical practices. As an example, a synbiotic with *Lactobacillus rhamnosus* and FOS can be of use to those who have low levels of Lactobacillus but not to those who have an effective population of the genus (Markowiak & Śliżewska, 2017). The fact that one can tailor synbiosis formulations according to microbial profiling is an important breakthrough in gut health management. Another field, where personalized nutrition has a chance to be effective, is the gut-brain axis, a two-way way of communication between the gut microbiota and central nervous system. Microbial products like SCFAs and neurotransmitter precursors have the ability to alter mood, cognition and immune. Specific nutritional interventions have proved to lessen anxiety and depression signs and symptoms, improve thinking capabilities, and regulate immune responses in autoimmune disorders. As an example, patients with low gut concentrations of *Faecalibacterium prausnitzii*, which is an anti-inflammatory bacterium, can take the benefit of *Faecalibacterium prausnitzii* synbiotics to increase its abundance. Increasing mental health and neurological health, personalized nutrition can affect the gut-brain axis.

Although there are a number of whole foods (garlic, onions, bananas, and asparagus) that are full of prebiotics, supplements provide accuracy and uniformity. Personalized supplementation typically entails testing of the microbiome to detect deficiencies of microbes and then use algorithms to give the appropriate recommendations and monitor them. A number of companies currently have microbiome analysis kits that produce customized diets plans after the analysis of the stool samples. These kits can give information on the microbial diversity, abundance of the major species, and possible imbalance. Despite the prospects, these tools still need to be thoroughly scientifically tested in order to guarantee the long-term effectiveness and safety (Sonnenburg and Sonnenburg, 2019). Personalized nutrition has many clinical applications that are growing at a high rate. Beneficial fiber intake can also be used to treat gastrointestinal diseases such as IBS and IBD to reduce their symptoms, including bloating, abdominal pain, and bowel irregularities. Synbiotics have been demonstrated to increase insulin sensitivity, decrease systemic inflammation and improve lipid profiles in metabolic diseases including obesity and type 2 diabetes (Kootte et al., 2017).

Further, gut flora modulation has been shown to support possible effects in the reduction of allergic reactions, the treatment of skin disorders such as eczema, and the increase in immunity. Recent clinical trial found out that personalized Synbiotics treatment was much better than the generic formulations in terms of improving IBS symptoms which showed the importance of the personal approach (Karl et al., 2025). This field is being dominated by technological innovations. Omics technologies, including genomics, metabolomics, and macrobiotics, can be used to profile the biology of individuals in detail. By using these tools, researchers and clinicians are able to know the interaction between genes, metabolites, and microbes to influence health. Dietary responses are predicted using microbiome data with the help of artificial intelligence, and microbiome editing using CRISPR-based methods has potential applications in the engineering of gut bacteria to carry out particular functions (Sheth et al., 2016). Wearable biosensors are also coming up, which have the capability of real-time monitoring of food metabolic responses. They are technologies that are making the future of nutritional approaches dynamic and responsive beyond the fixed meal plans.

The next era of personalized nutrition is that of its integration with other healthcare systems in the future. By integrating the data on microbiomes into the electronic health record, one may promote holistic care and allow clinicians to make an informed decision regarding dietary interventions. An increased number of microbiome databases will enhance the quality of the predictive model and enable subtle recommendations. The evolution of the next generation of synbiotics to fit microbial profiles which are rare will further improve the accuracy of the control of gut health. Nonetheless, such ethical issues like data privacy, accessibility and fair distribution are also to be contended with in order to make the advantages of personalized nutrition widely dispersed (Moore, 2020).

Recent studies have revealed previously unrecognized health benefits of prebiotics. The impact of enriching baby formula with prebiotics on the development of atopic dermatitis has been evaluated. The immunoactive oligosaccharides with prebiotic properties can efficiently prevent atopic dermatitis in infants with low atopy risk. Up to this point, the concept of prebiotics has been limited to the realms of nutraceuticals and pharmaceuticals. However, it is progressing quickly into cosmeceutical domains as well. It is suggested that prebiotic compounds could be used to influence a microbial community to gain beneficial results. Prebiotics are anticipated to address skin concerns such as inflammation and odor. Prebiotic products have demonstrated a remarkable 91% efficacy in human trials, indicating they can successfully reduce the population of Propionibacterium acnes and address acne. It is found that in obese mice, prebiotic consumption lowered firmicutes levels, while also decreasing fat accumulation, enhancing glucose tolerance, and reducing oxidative stress and inflammation. It was determined that prebiotics led to changes in gut flora, enhance glucose regulation, and could be a crucial approach in treating diabetes (Patel & Goyal, 2012). Probiotic treatment or microbial intervention is based on the concept of optimal gut flora. The provision of effective micro encapsulated beneficial bacteria will gain significance in the coming future. Micro-encapsulation will play a crucial role in supplying significant quantities of viable probiotic bacteria strains to consumers. It will function as a method to co-encapsulate both prebiotic components and probiotic microorganisms within a single capsule to improve the growth and proliferation of these bacteria via symbiotic interactions when released in the gastrointestinal system.

In the future, advancements in multiple-delivery systems may emerge, like co-encapsulating prebiotics, probiotics, and nutraceuticals, necessitating research into new, more complex nutritional matrices. In the processing of food, storage and preservation along with micro-encapsulation will more significantly contribute to safeguard the continued existence and growth of bacteria in challenging environmental conditions. Milk products, both non-fermented and fermented, sous-vide items, meat products, cereals, and prepared meal solutions could serve as food vehicles utilizing micro-packaging technology to safeguard beneficial bacteria, ensuring substantial quantities reach consumers.

## REFERENCES

Ahmad T, CP Tamboli, D Jewell et al., 2004. Clinical relevance of advances in genetics and pharmacogenetics of IBD. Gastroenterology 126:1533-49.

Akram W, N Garud & R Joshi, 2019. Role of inulin as prebiotics on inflammatory bowel disease. Drug Discoveries and Therapeutics 13:1-8.

Araújo MM & PB Botelho, 2022. Probiotics, prebiotics, and synbiotics in chronic constipation: Outstanding aspects to be considered for the current evidence. Frontiers in Nutrition 9:935830.

Aziz I, WE Whitehead, OS Palsson et al., 2020. An approach to the diagnosis and management of Rome IV functional disorders of chronic constipation. Expert Review of Gastroenterology and Hepatology 14:39-46.

Bischoff SC, 2011. Gut health: a new objective in medicine? BMC Medicine 9:24.

Blaut M & T Clavel, 2007. Metabolic diversity of the intestinal microbiota: Implications for health and disease. The Journal of Nutrition 137:751S-5.

Bouskra D, C Brézillon, M Bérard et al., 2008. Lymphoid tissue genesis induced by commensals through NOD1 regulates intestinal homeostasis. Nature 456:507-10.

Card T, R Hubbard & RF Logan, 2003. Mortality in inflammatory bowel disease: a population-based cohort study. Gastroenterology 125:1583-90.

Cencic A & W Chingwaru, 2010. The role of functional foods, nutraceuticals, and food supplements in intestinal health. Nutrients 2:611-25.

Cherry P, S Yadav, CR Strain et al., 2019. Prebiotics from seaweeds: An ocean of opportunity? Marine Drugs 17:327.

Chung H & DL Kasper, 2010. Microbiota-stimulated immune mechanisms to maintain gut homeostasis. Current Opinion in Immunology 22:455-60.

Collins S & G Reid, 2016. Distant site effects of ingested prebiotics. Nutrients 8:523.

Collins SM & P Bercik, 2009. The relationship between intestinal microbiota and the central nervous system in normal gastrointestinal function and disease. Gastroenterology 136:2003-14.

Connolly ML, JA Lovegrove & KM Tuohy, 2012. In vitro fermentation characteristics of whole grain wheat flakes and the effect of toasting on prebiotic potential. Journal of Medicinal Food 15:33-43.

Costabile A, F Fava, H Röytiö et al., 2012. Impact of polydextrose on the faecal microbiota: a double-blind, crossover, placebo-controlled feeding study in healthy human subjects. British Journal of Nutrition 108:471-81.

Cummings JH & GT MacFarlane, 2002. Gastrointestinal effects of prebiotics. British Journal of Nutrition 87:S145-51.

Davani-Davari D, M Negahdaripour, I Karimzadeh et al., 2019. Prebiotics: definition, types, sources, mechanisms, and clinical applications. Foods 8:92.

De-Souza DA & LJ Greene, 2005. Intestinal permeability and systemic infections in critically ill patients: effect of glutamine. Critical Care Medicine 33:1125-35.

Dethlefsen L, S Huse, ML Sogin et al., 2008. The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. PLOS Biology 6:e280.

Duchmann R, E Schmitt, P Knolle et al., 1996. Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to interleukin-12. European Journal of Immunology 26:934-8.

Gatt M, B Reddy & J MacFie, 2007. Bacterial translocation in the critically ill-evidence and methods of prevention. Alimentary Pharmacology and Therapeutics 25:741-57.

Gibson GR, R Hutkins, ME Sanders et al., 2017. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nature Reviews Gastroenterology and Hepatology 14:491-502.

Gibson GR & MB Roberfroid, 1995. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. The Journal of Nutrition 125:1401-12.

Gibson GR, K Scott, RA Rastall et al., 2010. Dietary prebiotics: current status and new definition. Food Sci. Technol. Bull. Funct. Foods 7:1-19.

Groschwitz KR & SP Hogan, 2009. Intestinal barrier function: molecular regulation and disease pathogenesis. Journal of Allergy and Clinical Immunology 124:3-20.

Guirro M, A Costa, A Gual-Grau et al., 2019. Effects from diet-induced gut microbiota dysbiosis and obesity can be ameliorated by fecal microbiota transplantation: A multiomics approach. PLOS One 14:e0218143.

Gullón B, B Gómez, M Martínez-Sabanjes et al., 2013. Pectic oligosaccharides: Manufacture and functional properties. Trends in Food Science and Technology 30:153-61.

Hidaka H, T Eida, T Takizawa et al., 1986. Effects of fructooligosaccharides on intestinal flora and human health. Bifidobacteria and Microflora 5:37-50.

Hidaka H, Y Tashiro & T Eida, 1991. Proliferation of bifidobacteria by oligosaccharides and their useful effect on human health. Bifidobacteria and Microflora 10:65-79.

Hsiao WW, C Metz, DP Singh et al., 2008. The microbes of the intestine: an introduction to their metabolic and signaling capabilities. Endocrinology and Metabolism Clinics of North America 37:857-71.

Hui YH, J Gorham, K Murrell et al., 1994. Foodborne disease handbook. Marcel Dekker, New York City, NY, USA.

Iapichino G, ML Callegari, S Marzorati et al., 2008. Impact of antibiotics on the gut microbiota of critically ill patients. Journal of Medical Microbiology 57:1007-14.

Jeong SH, YK Song & JH Cho, 2009. Risk assessment of ciprofloxacin, flavomycin, olaquindox and colistin sulfate based on microbiological impact on human gut biota. Regulatory Toxicology and Pharmacology 53:209-16.

Johnson CR, GF Combs Jr & P Thavarajah, 2013. Lentil (*Lens culinaris* L.): A prebiotic-rich whole food legume. Food Research International 51:107-13.

Karl JP, HS Fagnant, PN Radcliffe et al., 2025. Gut microbiota-targeted dietary supplementation with fermentable fibers and polyphenols prevents hypobaric hypoxia-induced increases in intestinal permeability. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 329:R378-99.

Kinross J, AC von Roon, N Penney et al., 2009. The gut microbiota as a target for improved surgical outcome and improved patient care. Current Pharmaceutical Design 15:1537-45.

Kinross JM, AC von Roon, E Holmes et al., 2008. The human gut microbiome: implications for future health care. Current Gastroenterology Reports 10:396-403.

Kleerebezem M & J Führen, 2024. Synergistic vs. complementary synbiotics: the complexity of discriminating synbiotic concepts using a Lactiplantibacillus plantarum exemplary study. Microbiome Research Reports 3:46.

Kootte RS, E Levin, J Salojärvi et al., 2017. Improvement of insulin sensitivity after lean donor feces in metabolic syndrome is driven by baseline intestinal microbiota composition. Cell Metabolism 26:611-19.e6.

Leu RKL, IL Brown, Y Hu et al., 2005. A synbiotic combination of resistant starch and Bifidobacterium lactis facilitates apoptotic deletion of carcinogen-damaged cells in rat colon. The Journal of Nutrition 135:996-1001.

Li HY, DD Zhou & RY Gan, 2021. Effects and mechanisms of probiotics, prebiotics, synbiotics, and postbiotics on metabolic diseases targeting gut microbiota: A Narrative Review. 13:3211.

Macfarlane GT, H Steed & S Macfarlane, 2008. Bacterial metabolism and health-related effects of galacto-oligosaccharides and other prebiotics. Journal of Applied Microbiology 104:305-44.

Mai V & PV Draganov, 2009. Recent advances and remaining gaps in our knowledge of associations between gut microbiota and human health. World Journal of Gastroenterology 15:81-90.

Markowiak P & K Śliżewska, 2017. Effects of probiotics, prebiotics, and synbiotics on human health. Nutrients 9:1021.

Moore JB, 2020. From personalised nutrition to precision medicine: the rise of consumer genomics and digital health. Proceedings of the Nutrition Society 79:300-10.

Pandey K, S Naik & B Vakil, 2015. Probiotics, prebiotics and synbiotics-a review. Journal of Food Science and Technology 52:7577-87.

Parnell JA & RA Reimer, 2010. Effect of prebiotic fibre supplementation on hepatic gene expression and serum lipids: a dose-response study in JCR:LA-cp rats. British Journal of Nutrition 103:1577-84.

Patel S & A Goyal, 2012. The current trends and future perspectives of prebiotics research: a review. 3 Biotech 2:115-25.

Pokusaeva K, GF Fitzgerald & D van Sinderen, 2011. Carbohydrate metabolism in Bifidobacteria. Genes and Nutrition 6:285-306.

Possemiers S, C Grootaert, J Vermeiren et al., 2009. The intestinal environment in health and disease-recent insights on the potential of intestinal bacteria to influence human health. Current Pharmaceutical Design 15:2051-65.

Preidis GA & J Versalovic, 2009. Targeting the human microbiome with antibiotics, probiotics, and prebiotics: gastroenterology enters the metagenomics era. Gastroenterology 136:2015-31.

Rhee SH, C Pothoulakis & EA Mayer, 2009. Principles and clinical implications of the brain-gut-enteric microbiota axis. Nature Reviews Gastroenterology and Hepatology 6:306-14.

Rinninella E, P Raoul, M Cintoni et al., 2019. What is the healthy gut microbiota composition? A changing ecosystem across age, environment, diet, and diseases. Microorganisms 7:14.

Round JL & SK Mazmanian, 2009. The gut microbiota shapes intestinal immune responses during health and disease. Nature Reviews Immunology 9:313-23.

Rowland I, C Rumney, J Coutts et al., 1998. Effect of Bifidobacterium longum and inulin on gut bacterial metabolism and carcinogen-induced aberrant crypt foci in rats. Carcinogenesis 19:281-85.

Sánchez-Zapata E, E Sendra, E Sayas et al., 2011. Resistant starch as prebiotic: A review. Stärke 63:406-15.

Scott KP, JC Martin, SH Duncan et al., 2014. Prebiotic stimulation of human colonic butyrate-producing bacteria and bifidobacteria, in vitro. FEMS Microbiology Ecology 87:30-40.

Sharma R, C Young & J Neu, 2010. Molecular modulation of intestinal epithelial barrier: contribution of microbiota. BioMed Research International 2010:305879.

Ain kertSheth RU, V Cabral, SP Chen et al., 2016. Manipulating bacterial communities by in situ microbiome engineering. Trends in Genetics 32:189-200.

Sonnenburg ED & JL Sonnenburg, 2019. The ancestral and industrialized gut microbiota and implications for human health. Nature Reviews Microbiology 17:383-90.

Sonnenburg ED, H Zheng, P Joglekar et al., 2010. Specificity of polysaccharide use in intestinal Bacteroides species determines diet-induced microbiota alterations. Cell 141:1241-52.

Spruss A & I Bergheim, 2009. Dietary fructose and intestinal barrier: potential risk factor in the pathogenesis of nonalcoholic fatty liver disease. The Journal of Nutritional Biochemistry 20:657-62.

Swanson KS, GR Gibson, R Hutkins et al., 2020. The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of synbiotics. Nature Reviews Gastroenterology and Hepatology 17:687-701.

Szilagyi A, 2005. Use of prebiotics for inflammatory bowel disease. Canadian Journal of Gastroenterology and Hepatology 19:505-10.

Tanaka M & J Nakayama, 2017. Development of the gut microbiota in infancy and its impact on health in later life. Allergology International 66:515-22.

Tanaka S, T Kobayashi, P Songjinda et al., 2009. Influence of antibiotic exposure in the early postnatal period on the development of intestinal microbiota. FEMS Immunology and Medical Microbiology 56:80-7.

Tsurugizawa T, A Uematsu, E Nakamura et al., 2009. Mechanisms of neural response to gastrointestinal nutritive stimuli: the gut-brain axis. Gastroenterology 137:262-73.

Tzounis X, A Rodriguez-Mateos, J Vulevic et al., 2011. Prebiotic evaluation of cocoa-derived flavanols in healthy humans by using a randomized, controlled, double-blind, crossover intervention study. The American Journal of Clinical Nutrition 93:62-72.

Valdes AM, J Walter, E Segal et al., 2018. Role of the gut microbiota in nutrition and health. BMJ 361:k2179.

Van Loo J, 2004. The specificity of the interaction with intestinal bacterial fermentation by prebiotics determines their physiological efficacy. Nutrition Research Reviews 17:89-98.

Vrieze A, F Holleman, E Zoetendal et al., 2010. The environment within: how gut microbiota may influence metabolism and body composition. Diabetologia 53:606-13.

Walker AW, J Ince, SH Duncan et al., 2011. Dominant and diet-responsive groups of bacteria within the human colonic microbiota. The ISME Journal 5:220-30.

Whelan K, 2013. Mechanisms and effectiveness of prebiotics in modifying the gastrointestinal microbiota for the management of digestive disorders. Proceedings of the Nutrition Society 72:288-98.

Yatsunenko T, FE Rey, MJ Manary et al., 2012. Human gut microbiome viewed across age and geography. Nature 486:222-7.

Yoo HD, D Kim & SH Paek, 2012. Plant cell wall polysaccharides as potential resources for the development of novel prebiotics. Biomolecules and Therapeutics 20:371-9.

Ze X, SH Duncan, P Louis et al., 2012. Ruminococcus bromii is a keystone species for the degradation of resistant starch in the human colon. The ISME Journal 6:1535-43.

Zeevi D, T Korem, N Zmora et al., 2015. Personalized nutrition by prediction of glycemic responses. Cell 163:1079-94.